Review

Immunotherapy and Radiation – A New Combined Treatment Approach for Bladder Cancer?

Zachary S. Buchwalda and Jason A. Efstathioub

aSaint Louis University School of Medicine, Saint Louis, MO, USA
bDepartment of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA

Abstract. Recently, immunotherapy with checkpoint inhibitors has been showing promise in clinical trials for stage IV bladder cancer. Herein, we review the literature regarding the role for radiation therapy, the role for immunotherapy, and the potential synergy of these treatments combined in bladder cancer. There is ample pre-clinical data in a number of different tumor models, coupled with a growing body of clinical evidence in melanoma and other malignancies to suggest combining radiation and immunotherapy could lead to substantial advances in treatment outcomes for bladder cancer. Yet, these data for bladder cancer remain at the pre-clinical stage, and further study is needed.

Keywords: Immunotherapy, radiation therapy, bladder cancer, checkpoint inhibitor, BCG, bladder-sparing therapy

ROLE OF RADIATION IN BLADDER CANCER TREATMENT

The standard of care for localized muscle-invasive bladder cancer (MIBC) is a consideration of neoadjuvant chemotherapy followed by radical cystectomy [1, 2]. The potential morbidity of this approach is well described [3, 4], and increases with age [5]. The effectiveness of trimodality therapy (transurethral resection of bladder tumor (TURBT) followed by chemoradiation) as a viable alternative to upfront cystectomy for selected patients with MIBC and for those either unwilling or unable to undergo surgery has also been evaluated [6-9]. Despite the lack of completed studies randomizing patients to either trimodality therapy or cystectomy, the available data suggests that outcomes can be similar between the two treatment approaches at comparable stages [10, 11]. A recent RTOG pooled analysis with a median follow-up of 7.8 years among survivors demonstrated a complete response (CR) rate to trimodality therapy of 72% [12], and a Massachusetts General Hospital study looking at long-term outcomes for trimodality therapy in MIBC showed a CR rate in 72% (78% in cT2) [13]. A small study also demonstrated that trimodality therapy for T2 recurrence after bacillus Calmette-Guérin (BCG) failure is viable with actuarial disease-specific survival (DSS) of 77% at 5 years and 70% at 7 years [14]. Furthermore, according to another RTOG pooled analysis, the reported rates of late pelvic toxicity following bladder-sparing therapy are low [15], and a quality of life (QOL) study based on patient reported data demonstrated high QOL among long-term survivors [16]. Indeed, the data seem encouraging that chemoradiation could play an important role in blad-
der cancer therapy for appropriately selected patients [6], and given these data it would seem only natural to explore new combinations with novel emerging immunotherapeutics.

The current recommendation for non-muscle invasive bladder cancer (NMIBC) including Ta, T1, and carcinoma in situ (CIS) is a TURBT followed by intravesicular chemotherapy or BCG with BCG recommended as the first line for CIS and a favored option for high-grade Ta and T1 disease [17, 18]. Data from the Surveillance, Epidemiology and End Results (SEER)-Medicare database has shown that BCG reduces bladder cancer deaths by 23% for patients with high-grade tumors [19]. In the absence of adjuvant therapy, the risk of progression to T2 or greater disease at 3 years approaches 50% [20, 21].

Despite the well-established benefit of BCG therapy, a substantial proportion of patients who receive it will still develop BCG refractory disease [21–23]. In these cases the standard recommendation has been cystectomy. As a potential alternative, Weiss et al. demonstrated an 88% complete response rate with radiotherapy following TURBT for high risk T1 disease [24], and currently RTOG 0926 is investigating the effectiveness of trimodality therapy in recurrent BCG refractory T1 disease. In fact, prior to the widespread use of BCG, radical radiotherapy was used to treat T1 disease, but this fell out of favor following a phase III comparison between radiotherapy alone versus conservative measures (including BCG) that showed no difference in overall or progression free survival [25, 26]. NCCN guidelines currently dictate that radiation therapy can be considered for poor surgical candidates with recurrent T1 disease [1]. As will be described later, radiation in combination with other immunomodulatory drugs, in fact, may be the ideal treatment for restimulating an immune system that is no longer functionally responsive to BCG.

IMMUNOTHERAPY FOR BLADDER CANCER

An association between febrile illness and cancer regression has been known for centuries [27]. However, it was not until the 19th century that surgical oncologist William Coley demonstrated, using a systematic approach of injecting a mixture of heat-killed Streptococcus pyogenes and Serratia marcescens into 210 patients with soft-tissue sarcomas, that the immune system’s impact could be more accurately quantified. A response was observed in 60 patients, but it would take time before cancer immunotherapy gained broader mainstream acceptance.

Tumor growth requires modulation and suppression of the immune system. It is known that the incidence of malignancies increases in immunosuppressed individuals [28, 29]. In addition, the immunosurveillance hypothesis, in which organisms are under constant thymic-dependent surveillance for neoplastic growth originally postulated by F. MacFarlane Burnett, has gained added traction with later supporting studies [29–32]. This idea was further modified by Robert Schreiber who described a process of “immunediting”. According to Schreiber, a malignancy undergoes three phases before becoming clinically relevant: 1) the elimination phase or the classical concept of immunosurveillance; 2) the equilibrium phase in which a metastable state is reached between tumor and immune system; and 3) the escape phase in which the tumor has developed immuno- evasive and suppressive mechanisms under the harsh evolutionary pressure of the immune system, thereby allowing it to grow unencumbered [33, 34]. To effectively harness the immune system against cancer these latter evolved barriers must be overcome.

Overcoming the high threshold of tumor immune tolerance is the goal of immunotherapy. There are a number of approaches which range from improving endogenous tumor antigen presentation and lymphocyte activation to ex-vivo manipulation of lymphocytes and re-infusion [35, 36]. Improved antigen presentation occurs with increased tumor antigen liberation and the endogenous production or exogenous addition of adjuvants necessary to fully mature/activate dendritic cells. BCG, a robust adjuvant and a product not dissimilar to the original Coley’s toxin, is the fore- runner to all other immunotherapy being trialed for NMIBC. Its effective application is already an indication that influencing T-cell responses can impact bladder cancer’s risk of recurrence. In fact, in one study it was shown that a febrile response to BCG was a good prognostic factor and correlated with longer recurrence free survival [37]. Urinary IL-2, a potent T-cell mitogen, and IL-2 production by peripheral blood lymphocytes (PBL) also were prognosticators of a good response to BCG. Thalmann et al. demonstrated that patients with elevated urinary IL-18, a molecule critical for effective T cell responses, have significantly longer disease free survival [38]. Using a mouse model, Biot et al. suggested that T-cell memory is likely involved in robust anti-tumor activity following intravesicular BCG administration as prior exposure to BCG enhances the anti-tumor immune system’s impact.
response. The authors show that the recruitment of inflammatory monocytes into the bladder was abrogated by CD4 and CD8 T-cell depletion prior to intravesicular BCG instillation. Additionally, repeated BCG instillations also increased the numbers of T-cells infiltrating the bladder. Finally, the authors show in a clinical series of 55 patients, who were stratified by PPD positivity before intravesical BCG therapy, that prior exposure to mycobacterium confers a significantly better recurrence-free survival. This again indicates that a likely anamnestic response is at work [39]. All these observations are consistent with Sharma et al. who previously demonstrated that higher numbers of CD8^+ tumor-infiltrating lymphocytes in muscle invasive disease correlates with superior disease-free and overall survival [40]. Alternatively, other studies have shown that certain genetic signatures can also be predictive of a BCG response [41, 42], specifically polymorphisms in oxidative stress genes [43]. Despite BCG being an established adjuvant for bladder cancer, BCG failure remains a concern.

BCG failure can occur due to patient intolerance to the side effects or tumor resistance to or recurrence following the treatment. BCG intolerance is relatively common, occurring in 20% of patients during maintenance therapy. These patients then require intravesicular therapy with an alternate agent [44, 45]. In contrast, patients who were able to tolerate BCG and had an initial response were reported to have a 38.6% recurrence rate after a median follow-up of 26 months [46]. BCG unresponsiveness is defined as persistent high grade tumor at 6 months or a recurrence within 6 months or less after achieving a disease-free state [47, 48]. Herr and Dalbagni showed that at 6 months 20% of BCG treated patients had persistent or recurrent tumors. In addition to the cytokines described earlier that correlate with a good response to BCG, there is evidence to suggest an aberrant Th2 response instead of a robust Th1 response is associated with failure [49, 50].

Alternative approaches to cystectomy have been examined following BCG failure. Interferon-α2b (IFN-α2b) in combination with BCG was studied in a multicenter Phase II trial including 231 patients with BCG failure. These patients were treated with a 6-week induction course of BCG and IFN-α, followed by 3 additional treatments. With a median follow-up of 2 years, 57.3% of BCG naïve patients and 42% of the patients with prior BCG failure remained tumor free [51]. However, one randomized trial examining BCG combined with IFN-α2b did not show superiority compared to BCG alone for BCG naïve patients [52, 53]. Nevertheless, IFN-α2b may still be effective in BCG failure patients because it has been shown in-vitro to inhibit production of IL-10, an immunosuppressive cytokine, allowing potentiation of the Th1 response [54]. IL-10 has been shown to impair the antitumor activity of intravesicular BCG therapy with IL-10 knockout mice demonstrating enhanced delayed-type hypersensitivity and an enhancement of the antitumor response [55]. Finally combined BCG and IL-12, in an effort to skew the immune response towards a dominant Th1 phenotype, appears to have some potential efficacy in animal models [56].

Bladder cancer along with melanoma and non-small cell lung cancer represent good candidates for cell-mediated immunotherapy due to their relatively high somatic mutation rates [57]. This generates many novel tumor antigens [57, 58] that are critical for an effective immune response because it creates a variety of epitopes that may differ from native peptides and to which T-cells have not been negatively selected. For effective T-cell activation, T-cells require three signals: 1) effective TCR ligation by its cognate MHC-antigen complex, 2) co-stimulation through CD28 on the T-cell membrane, and 3) a cytokine milieu that determines the T-cells’ phenotype. There are also negative regulators of T-cell activation including CTLA-4 and PD-1 which increase the T-cell activation threshold or impair its effector function. Current immunotherapy has focused on disrupting these negative regulators, termed checkpoint blockade, thereby increasing the chance for a functional adaptive immune response. Another group of molecules which include OX40 (CD134) and CD40 are activating receptors on T-cells and antigen presenting cells (APC) respectively. These are also being targeted with agonistic antibodies to promote an anti-tumor response. These biologics are an exciting addition to bladder cancer given the lack of effective therapeutic options for advanced disease [59, 60]. Initial results are encouraging and are examined in more detail here [61].

The newer checkpoint inhibitors improve treatment outcomes for localized as well as metastatic disease. Checkpoint blockade of CTLA-4 using ipilimumab, first approved by the FDA in 2011, has demonstrated encouraging results for unresectable and metastatic melanoma [62, 63]. This drug acts at the initial point of T-cell activation, recruiting T-cells to the immune response that would not normally have received the threshold trigger for activation. Ipilimumab has also been shown to impact regulatory T-cell number and function in a few pre-clinical studies [64, 65]. Carthorn et al. at MD Anderson showed in a small dose esca-
ation study of ipilimumab for localized urothelial carcinoma of the bladder that there was limited toxicity. They also noted an increased frequency of CD8+ T cells + is pre-exsisting intra-urothelial T-cell clones. in the systemic circulation of these patients [66]. There is currently an on-going phase II clinical trial (NCT01524991) examining the combination of gemcitabine, cisplatin and ipilimumab for metastatic urothelial carcinoma with a primary outcome measurement of one-year overall survival.

The standard of care for stage IV bladder cancer remains platinum-based chemotherapy regimens-methotrexate, vinblastine, doxorubicin, cisplatin (MVAC), high dose MVAC and methotrexate, cisplatin and vinblastine (MCV) - which have demonstrated a survival benefit. The 5-year overall survival for MVAC is 15.3% [67]. Additionally, MVAC is associated with a substantial toxic death rate and toxicities that can reach 4% [68]. Any addition to our armamentarium has the potential for lasting consequences, and disruption of the PD-1/PD-L1 axis appears likely to be one of the most promising recent developments. PD-1, another negative regulator of T-cell activation, can encounter its ligand, PD-L1, in multiple places including tumor cells and tumor-infiltrating immune cells. A phase I trial for lambrolizumab (anti-PD-1) in advanced melanoma enrolled 135 patients, 48 of whom had received prior treatment with ipilimumab. 13% of patients reported grade 3 or 4 toxicity, and the overall response rate (ORR) was 44% which did not vary with prior exposure to ipilimumab. Regressing lesions which were biopsied showed densely infiltrated CD8+ T-cells [69]. Data from Tumeh et al. suggests that pre-existing intratumoral CD8+ T-cells are responsible for tumor regression in advanced melanoma following PD-1 blockade [70]. The authors were able to develop a predictive model for response to PD-1 inhibition based on CD8+ T-cell density at the tumor invasive margin. This was validated in an independent 15 patient cohort. These studies of PD-1/PD-L1 disruption have been extended to bladder cancer.

Recent data from Powles et al. demonstrated in an expanded phase I trial with 67 metastatic bladder cancer patients treated with MPDL3280A (anti-PD-L1) that there was an objective response rate of 11% for patients with PD-L1 negative/low and 43% for PD-L1 intermediate/high expressing tumor-infiltrating immune cells. Interestingly, in this study the response rate was dependent on PD-L1 expression by the tumor infiltrating immune cells (likely myeloid-derived suppressor cells) rather than the tumor cells themselves [61, 71]. This has also been seen in non-small cell lung cancer and renal cell carcinoma [72]. An abstract presented at the European Society for Medical Oncology in 2014 showed encouraging results for pembrolizumab (anti-PD-1) for patients with advanced urothelial tumors [73]. Another recently published study from Harvard, showed that expression of PD-L1 by tumor-infiltrating mononuclear cells (TIMCs) correlated with improved overall survival even in patients treated only with platinum-based chemotherapy. This is consistent with the notion that PD-L1 expression by TIMCs is induced following intratumoral T-cell activation and cytokine production [74]. Of note, it has also been reported that PD-L1 expression is dynamic and PD-L1 upregulation may be an effective surrogate marker for T-cell activation and lytic potential [75]. There are a number of clinical trials (NCT02302807, NCT02108652) still recruiting which are testing the role of MPDL3280A in locally advanced and metastatic bladder carcinoma, in addition to trials testing anti-PD-1 inhibitors (NCT02324582).

Another approach being examined for a variety of metastatic malignancies including bladder cancer is the use of a fusion protein consisting of IL-2 and a humanized soluble T-cell receptor directed against p53 derived epitopes (ALT-801). A number of malignancies, including bladder cancer, overexpress p53 and therefore this approach confers a level of specificity [76, 77]. A phase I trial with a heterogeneous collection of advanced malignancies demonstrated reasonable tolerability and encouraging efficacy [78]. Currently there are trials (NCT01625260) examining ALT-801 in BCG refractory NMIBC or an engineered IL-15 super-agonist (ALT-803) in combination with BCG (NCT02138734) also for NMIBC. Another interesting approach involves an engineered adenovirus, CG0070, which preferentially replicates in RB protein-defective human-derived tumors that there was limited toxicity. They also noted an increased frequency of CD8+ T cells + is pre-exsisting intra-urothelial T-cell clones. in the systemic circulation of these patients [66]. There is currently an on-going phase II clinical trial (NCT01524991) examining the combination of gemcitabine, cisplatin and ipilimumab for metastatic urothelial carcinoma with a primary outcome measurement of one-year overall survival.

The standard of care for stage IV bladder cancer remains platinum-based chemotherapy regimens-methotrexate, vinblastine, doxorubicin, cisplatin (MVAC), high dose MVAC and methotrexate, cisplatin and vinblastine (MCV) - which have demonstrated a survival benefit. The 5-year overall survival for MVAC is 15.3% [67]. Additionally, MVAC is associated with a substantial toxic death rate and toxicities that can reach 4% [68]. Any addition to our armamentarium has the potential for lasting consequences, and disruption of the PD-1/PD-L1 axis appears likely to be one of the most promising recent developments. PD-1, another negative regulator of T-cell activation, can encounter its ligand, PD-L1, in multiple places including tumor cells and tumor-infiltrating immune cells. A phase I trial for lambrolizumab (anti-PD-1) in advanced melanoma enrolled 135 patients, 48 of whom had received prior treatment with ipilimumab. 13% of patients reported grade 3 or 4 toxicity, and the overall response rate (ORR) was 44% which did not vary with prior exposure to ipilimumab. Regressing lesions which were biopsied showed densely infiltrated CD8+ T-cells [69]. Data from Tumeh et al. suggests that pre-existing intratumoral CD8+ T-cells are responsible for tumor regression in advanced melanoma following PD-1 blockade [70]. The authors were able to develop a predictive model for response to PD-1 inhibition based on CD8+ T-cell density at the tumor invasive margin. This was validated in an independent 15 patient cohort. These studies of PD-1/PD-L1 disruption have been extended to bladder cancer.

Recent data from Powles et al. demonstrated in an expanded phase I trial with 67 metastatic bladder cancer patients treated with MPDL3280A (anti-PD-L1) that there was an objective response rate of 11% for patients with PD-L1 negative/low and 43% for PD-L1 intermediate/high expressing tumor-infiltrating immune cells. Interestingly, in this study the response rate was dependent on PD-L1 expression by the tumor infiltrating immune cells (likely myeloid-derived suppressor cells) rather than the tumor cells themselves [61, 71]. This has also been seen in non-small cell lung cancer and renal cell carcinoma [72]. An abstract presented at the European Society for Medical Oncology in 2014 showed encouraging results for pembrolizumab (anti-PD-1) for patients with advanced urothelial tumors [73]. Another recently published study from Harvard, showed that expression of PD-L1 by tumor-infiltrating mononuclear cells (TIMCs) correlated with improved overall survival even in patients treated only with platinum-based chemotherapy. This is consistent with the notion that PD-L1 expression by TIMCs is induced following intratumoral T-cell activation and cytokine production [74]. Of note, it has also been reported that PD-L1 expression is dynamic and PD-L1 upregulation may be an effective surrogate marker for T-cell activation and lytic potential [75]. There are a number of clinical trials (NCT02302807, NCT02108652) still recruiting which are testing the role of MPDL3280A in locally advanced and metastatic bladder carcinoma, in addition to trials testing anti-PD-1 inhibitors (NCT02324582).

Another approach being examined for a variety of metastatic malignancies including bladder cancer is the use of a fusion protein consisting of IL-2 and a humanized soluble T-cell receptor directed against p53 derived epitopes (ALT-801). A number of malignancies, including bladder cancer, overexpress p53 and therefore this approach confers a level of specificity [76, 77]. A phase I trial with a heterogeneous collection of advanced malignancies demonstrated reasonable tolerability and encouraging efficacy [78]. Currently there are trials (NCT01625260) examining ALT-801 in BCG refractory NMIBC or an engineered IL-15 super-agonist (ALT-803) in combination with BCG (NCT02138734) also for NMIBC. Another interesting approach involves an engineered adenovirus, CG0070, which preferentially replicates in RB protein-defective
IMMUNOLOGIC EFFECTS OF RADIATION THERAPY IN BLADDER CANCER

Much has been written recently about the immunostimulatory effects of radiation [82–84] (see Fig. 1). Although still somewhat controversial, there is a growing body of evidence that immunogenic cell death induced by radiation liberates tumor antigens along with endogenous adjuvants promoting APC maturation and effective cytotoxic T-cell priming [85]. Radiation induced immunogenic cell death is characterized, in part, by activation of the endoplasmic reticulum (ER) stress pathway and tumor cell surface expression of calreticulin (CRT), a pro-phagocytic molecule, facilitating APC uptake of tumor antigens [86]. In addition, passive secretion of HMGB1, an evolutionarily conserved nuclear protein, by tumor cells undergoing late apoptosis or necrosis can bind toll-like receptor 4 (TLR-4), the lipopolysaccharide (LPS) receptor, on dendritic cells (DC) and lead to DC maturation and effective T-cell priming [87, 88]. Radiation has also been shown to promote effector T-cell recruitment into the tumor through chemokine induction and upregulation of tumor cell MHC-I expression. Prior to RT, many tumors secrete chemokines which recruit immunosuppressive cells including regulatory T-cells [89, 90]. However, radiation in a 4T1 mouse breast cancer model induces CXCL16 production, a chemokine which recruits effector T-cells and whose expression correlates with increased numbers of tumor-infiltrating lymphocytes and improved survival [91, 92]. Radiation also induces a bystander effect influencing tumor cell survival through its effects on stromal components. The bystander effect is largely mediated by stromal cell-cell communication through gap junctions or production of soluble mediators including tumor necrosis factor-α which may help mature APCs for effective antigen presentation [93, 94]. Finally, and perhaps most importantly, there is data that demonstrates radiation and checkpoint inhibitors activate the immune system through two non-redundant mechanisms [65]. Twyman Saint-Victor et al. show that radiation enhances the diversity of the T-cell receptor repertoire intratumorally while anti-CTLA4 promotes expansion of effector T-cells, and anti-PD-L1 reverses T-cell exhaustion. It is these non-overlapping mechanisms that make clinical synergy so exciting.

In the specific context of urinary bladder carcinoma, O’Toole et al. used an interesting technique to evaluate the effect of tumor irradiation on PBL cytotoxicity. In this study, patients with T1-T4 bladder cancer received radiation using a three-field technique (two anterior wedge fields and an open posterior field). Prior to, during, and following radiation, patient PBL were collected and cultured with target cells to assess cytotoxicity, and it was shown that two of three patients with T3 cancer who were negative for PBL cytotoxic activity prior to radiation were positive afterwards [95]. In a follow-up study, the authors demonstrated that the patients who were clinically tumor free 5 years after treatment all had a more rapid post-radiotherapy increase in lymphocyte numbers than the patients who recurred again suggesting that adaptive immunity plays a role in bladder cancer control [96].

There is a subsequent report that irradiation of bladder carcinoma cell lines may enhance their susceptibility to NK cell mediated killing. Mizutani et al. showed that T24, a known NK cell resistant bladder cancer cell line, was increasingly sensitive to lysis following as little as 1 Gy of radiation. This effect is likely not antigen specific, but further suggests the immunoenhancing effects of ionizing radiation in bladder cancer [97]. More recently, Demaria et al. demonstrated in a pre-clinical model that if a DC growth factor promoting results after receiving a CTLA-4 antagonist may help mature APCs for effective antigen presentation [93, 94]. In a follow-up “proof-of-principle” clinical trial, 14 patients with advanced metastatic disease, including bladder cancer, were treated with GM-CSF and received radiation to one lesion at 3.5 Gy x 10 fractions over 2 weeks. The overall results were encouraging with 30% achieving an abscopal response, while others showed a decreased SUV of non-irradiated lesions [99]. Admittedly, at this time most studies examining this exciting synergy between radiation and immunotherapy are not focused on urinary bladder cancer (Fig. 1).

In patients with metastatic cutaneous melanoma there have been a number of case studies reporting encouraging results after receiving a CTLA-4 antagonist and radiation [100, 101]. A report out of Memorial Sloan Kettering followed a 39 year old woman with diffuse disease who received palliative radiation to a paraspinal metastasis while also receiving ipilimumab. Four months following treatment, imaging showed regression of both the irradiated lesion and uniradiated distant metastases [101]. NCT01689974 is a phase II trial evaluating ipilimumab alone versus ipilimumab and radiation in metastatic melanoma. A number of clinical trials are investigating this interaction in a variety of other malignancies including non-small cell lung cancer (NCT0221739) and head and neck cancer (NCT01935921). NCT00861614 is a...
completed phase 3 trial evaluating radiation and ipilimumab for castration-resistant prostate cancer. The primary outcome measure was overall survival and it compared ipilimumab plus radiation to radiation alone for patients that had received prior treatment with docetaxel. Results published in 2014 demonstrated no statistically significant (p-value = 0.053) difference between the ipilimumab and placebo groups, however, the authors do state the overall survival hazard ratio decreased over time and ipilimumab at later time points correlated with improved survival relative to placebo [102]. Additionally, a subgroup analysis of patients with more favorable prognostic features including an alkaline phosphatase less than 1.5 times the upper limit of normal, a hemoglobin concentration of 110 g/l or higher and no visceral metastases showed a median overall survival with ipilimumab of 22.7 months compared to 15.8 months with placebo and a p-value of 0.0038.

The PD-1 axis inhibitors and radiation are being evaluated in pre-clinical models with data suggesting improved local tumor control [103] and this interaction is also being investigated in some upcoming clinical trials (Table 1). As a parallel, there have also been a number of trials demonstrating an improved response rate when multiple immunomodulatory drugs are combined in renal cell carcinoma and melanoma—perhaps physiologically analogous to a combined radiation/immunotherapeutic approach [104, 105]. Results from clinical trials evaluating radiation therapy and PD-1/PD-L1 blockade are still outstanding.

There is no overriding consensus about the timing of radiation relative to immunotherapy although initial data seems to support concurrent administration. In a pre-clinical trial, commencing anti-PD-L1 administration on either the first or the last day of radiation had equivalent overall survival, but both were superior to commencing PD-L1 blockade 7 days after radiation completion [106]. Administering radiation following immunotherapy could potentially blunt an already active response [84]. There is also limited data with regards to optimal dose and fractionation of the radiation with immunotherapy. For induction of an abscopal effect, preclinical data suggests a fractionated regimen is superior to a single dose 24 Gy in 3 is superior
| Clinical trials.gov identifier | Sponsor | Immunotherapy | Radiotherapy | Treatment timing | Phase | Condition |
|-------------------------------|---------|---------------|--------------|------------------|-------|-----------|
| NCT01436968                  | Advantagene, Inc | ProstAtak (AdV-tk) injected into prostate | Standard of care | Radiation 0–3 days after second AdV-tk injection | 3 | Prostate Cancer |
| NCT00751270                  | Advantagene, Inc | AdV-tk injected into tumor/tumor bed | Standard of care | Radiation 3–7 days following AdV-tk injection | 1b | Malignant Glioma |
| NCT00589875                  | Advantagene, Inc | AdV-tk injected into tumor bed | Standard of care | Radiation 3–7 days following AdV-tk injection | 2a | Malignant Glioma |
| NCT00634231                  | Advantagene, Inc | AdV-tk injected into tumor/tumor bed | Standard of care | Radiation 3–7 days following AdV-tk injection | 1 | Pediatric Brain Tumors |
| NCT00589875                  | Advantagene, Inc | AdV-tk injected into tumor bed | Standard of care | Radiation 3–7 days following AdV-tk injection | 2 | Malignant Glioma |
| NCT01836432                  | NewLink Genetics Corporation | Algenpantucel-L (HAPa1, HAPa2) | 50.4 Gy in 28 fractions | Radiation and immunotherapy on day 1 | 3 | Pancreatic Cancer |
| NCT01896271                  | University of Texas Southwestern Medical Center | High-dose IL-2 Stereotactic ablative radiation therapy (SART) 8–20 Gy in 1–3 fractions | IL-2 administered immediately following radiation | 2 | Metastatic Renal Cancer |
| NCT01497488                  | Abramson Cancer Center of the University of Pennsylvania | Ipilimumab Dose escalation for Stereotactic body radiation therapy (SBRT) Not described | Not described | 1/2 | Metastatic Melanoma |
| NCT02303990                  | Abramson Cancer Center of the University of Pennsylvania | Pembrolizumab (anti-PD-1) Hypofractionated radiation | Not described | 1 | Metastatic Cancers |
| NCT02086721                  | Maastricht Radiation Oncology | L19-IL-2 Patients receive a schedule of 1 x 30 Gy, 3 x 15–20 Gy, 5 x 12 Gy, 8 x 7.5 Gy | L19-IL-2 given one week after completion of radiation | 1 | Oligometastatic Solid Tumors |
| NCT01933921                  | National Cancer Institute | Ipilimumab Standard of care | Ipilimumab started at beginning of week 4 of cetuximab course, given 3 courses total Radiation day 0, AMP-224 on day 1 then q14 days | 1 | Stage III-IVB Head and Neck Cancer |
| NCT02208946                  | National Cancer Institute | AMP-224 (PD-1 inhibitor) Stereotactic body radiation therapy | Radiation day 0, AMP-224 on day 1 then q14 days | 1 | Metastatic Colorectal Cancer |
| Clinical trial identifier | Sponsor | Immunotherapy | Radiotherapy | Treatment timing | Phase | Condition |
|--------------------------|---------|---------------|--------------|------------------|-------|-----------|
| NCT02359900              | M.D. Anderson Cancer Center | Ipilimumab | Depends on group - SBRT 50 Gy in 4 fractions (group 1) | Depends on group - Radiation days 1–4 of cycle 1 of ipilimumab (group 1) | 1/2 | Advanced Solid Tumors |
| NCT01648974              | New York University School of Medicine | Ipilimumab | 6 Gy × 5 IMRT | Ipilimumab first given day 4 after radiation | 2 | Melanoma |
| NCT02221739              | New York University School of Medicine | Ipilimumab | 6 Gy × 5 IMRT | Ipilimumab first given within 24 hours of starting radiation | 2 | Melanoma |
| NCT01276730              | James Graham Brown Cancer Center | Interferon-α2b | 40–45 Gy in conventional fx to whole pelvis Conventional radiation with boost | Radiation begins prior to DC injection | 2 | Melanoma |
| NCT0149270              | Stanford University | Ipilimumab | Palliative radiation | Ipilimumab given up to two days before radiation | 1 | Melanoma |
| NCT0254772              | Stanford University | TLR-9 agonist (SD-101), ipilimumab | Not specified | SD-101 given intratumoral given starting day 1 and ipilimumab given on day 1, radiation on days 1,2 | 1/2 | Low-Grade Recurrent B-Cell Lymphoma |
| NCT01565837              | Wolfram Samloewski | Ipilimumab | Stereotactic ablative radiation | Radiation to 1–5 lesions after initial dose of ipilimumab | 2 | Melanoma |
| NCT01758458              | Fred Hutchinson Cancer Research Center | MCPyV TAg-specific polyclonal autologous CD8-positive T-cell vaccine | Unspecified | Radiation is given day 2 to 4 before treatment | 1 | Merkel Cell Carcinoma |
| NCT0230366               | Peter MacCallum Cancer Center, Australia | MK-3475 (anti-PD-1) | Stereotactic ablative radiation | Radiation followed by 8 cycles of MK-3475 | 1 | Oligometastatic Breast Neoplasia |
| NCT0231871               | Thomas Jefferson University | MK-3475 | Radiation day 1, MK-3475 3–17 days later | 1 | Many Advanced Cancers |
| NCT01703507              | Thomas Jefferson University | Ipilimumab | Whole brain or stereotactic radiation | Receive ipilimumab 4 × over 10 weeks. WBRT done for weeks 1,2, | 1 | Melanoma with Brain Metastases |
to 30 Gy in 5 which is superior to 20 Gy in 1 fraction [107, 108]. Clinical data has demonstrated absopical effects for a variety of different fractionation regimens including 8 Gy in one and 30 Gy in five fractions [107, 109, 110]. Although specific dosing information has yet to be fully established, data from pre-clinical studies also suggests that increasing dose leads to increased interferon-γ production and improved antigen presentation, the caveat being that at higher doses there appears to be a concurrent rise in regulatory T-cells [111, 112]. Currently, when evaluating the data in totality, it is difficult to make a specific recommendation, but a dose of 8 Gy in one fraction up to 24 Gy in three fractions given with a concurrent checkpoint inhibitor appears to be the most well supported treatment regimen based on the above preclinical data and the encouraging results from NCT0861614 (ipilimumab with radiation for castration-resistant prostate cancer) which gave radiations within 2 days of initiating ipilimumab.

Melanoma has been at the forefront of the radioimmunotherapy clinical trials but it is now time to incorporate urinary bladder cancer. It was one of the first malignancies in which an effective immunotherapy was utilized, and it behooves us to examine potential synergy with radiation. There are numerous contexts in which this combination therapy could be applied including BCG refractory NMIBC. A new phase of RT0G 0926 could include a checkpoint inhibitor and an immune activating dose of radiation (such as 8 Gy x 1). Alternatively, further investigation may yield a novel hypo fractionated regimen that in combination with immunotherapy optimizes radiation antigenicity. Immunotherapy could also be added as an upfront component of trimodality therapy for MIBC, or for use in salvage following trimodality therapy failure in MIBC or in non-muscle invasive disease. Finally, immunotherapy may even have an application in combination with radiation for metastatic disease to evaluate the likelihood of an abscopal response.

CONCLUSION

In conclusion, both radiation and immunotherapy are playing an increasingly important role in a number of malignancies including bladder cancer. It is evident that immunotherapy has great potential to improve survival for patients with both localized and advanced disease. This potential may be improved even further if these novel immunotherapeutic modalities are combined with radiation. Using melanoma as the model, there seems to be reason for great excitement for the future of bladder cancer therapy.

REFERENCES

[1] National Comprehensive Cancer Network (NCCN.org). Bladder Cancer. 2015 [cited 2015 Feb 9]. Available from: http://www.nccn.org/professionals/physician_gls/pdf/bladder.pdf
[2] Grossman HB, Natkunam Y, Tangen CM, Speights VO, Vogelzang NJ, Trump DL, deWit RC, Bajorin DF, Wood DP Jr, Buggage DR, Crawford ED, Nonsurgical chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 2003;349(9):859-66.
[3] Shabani A, Kérisi M, Vugia DJ, Lebenthal A, Reuter VE, Bostwick DG, Greenberg FS. Defining early morbidity of radical cystectomy for patients with bladder cancer using a standardized reporting methodology. Eur Urol 2009;55(1):364-74.
[4] Bostwick DG, Balbagno G, Sibbald DD, Silbernagel J, Keren Piz G, Donat SM, Coleman JA, Mathew S, Vickers A, Scher HC, Forsterstein MA, Raptop B, Parisi BO, Herr HW, Lavalone VP. Computing Open Radical Cystectomy and Robot-assisted Laparoscopic Radical Cystectomy: A Randomized Clinical Trial. Eur Urol 2014; Dec 8 [cited 2015 Feb 10]. doi: 10.1016/j.eururo.2014.11.043 [Epub ahead of print].
[5] Fischler M, Bruns MA, Herr HW, Muto G, Studer UE. Complications following radical cystectomy for bladder cancer in the elderly. Eur Urol 2009;56(1):440-54.
[6] Gué G, Efstathiou JA, Lerner SP, Cookson MS, Kogan KA, Gurka KA, Shipley WU, Heidenreich A, Scherhorn JP, Sagalowsky AS, Soloway MS, Stenzl A, International Consultation on Urologic Disease-European Association of Urology Consultation on Bladder Cancer 2012. Radiation cystectomy and bladder preservation for muscle-invasive urothelial carcinoma of the bladder. Eur Urol 2013;63(1):65-7.
[7] Kaufman DS, Shipley WU, Griffin PP, Heney NM, Althausen AF, Eifret JT, Selective bladder preservation by combination treatment of invasive bladder cancer. N Engl J Med 1993;329(19):1377-82.
[8] Ploussard G, Dedesianand S, Efstathiou JA, Herr HW, James ND, Rosell CM, Shariat SF, Shipley WU, Steinberg CN, Thalhammer GN, Kassouf W. Critical analysis of bladder sparing with trimodal therapy in muscle-invasive bladder cancer: A systematic review. Eur Urol 2014;66(1):220-37.
[9] James ND, Hussain SA, Hall E, Jenkins P, Tremlett J, Rawlings CA, Grundy M, Sizer B, Stenvisas T, Henderson C, Lewis R, Waters R, Huddart RA, Investigators BC. Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. N Engl J Med 2012;366(16):1477-86.
[10] Chen RC, Shipley WU, Efstathiou JA, Zietman AL. Trimmality bladder preservation therapy for muscle-invasive bladder cancer. J Natl Compr Canc Netw 2013;11(8):952-60.
[11] Huddart RA, Hall E, Lewis R, Birtle A, Groop SM. Life and death of spare (selective bladder preservation against radical excision): Reflections on why the spare trial closed. BJU Int 2010;106(6):753-5.
[12] Mak RH, Hunt D, Shipley WU, Efstathiou JA, Tozer WM, Hogan MF, Kaufman DS, Heney NM, Zietman AL. Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preservation combined-modality therapy: A pooled analysis of Radiation Therapy Oncology Group protocols 8802, 8903, 9506, 9706, 9906, and 0233. J Clin Oncol 2014;32(34):3801-9.
24  

[13] Efstathiou JA, Spiegel DV, Shipley WU, Henry NM, Kaufman DS, Niemerko A, Coen JJ, Skovronski RV, Paly GO, McGowan PJ, Zietman AL. Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: The MGH experience. Eur Urol 2012;61(4):705-11.

[14] Wo JY, Shipley WU, Dahl DM, Coen JJ, Heney NM, Wo JY, Shipley WU, Dahl DM, Coen JJ, Heney NM. Late pelvic toxicity after bladder-sparing therapy in patients with invasive bladder cancer: Is immediate cystectomy always necessary? BJU Int 2009;104(2):170-9.

[15] Harland SJ, Kynaston H, Grigor K, Wallace C, Kockelbergh R, Clawson S, Barlow T, Parmar MK, Griffiths GO. National Cancer Research Institute Bladder Clinical Studies G. A randomized trial of radical radiotherapy for the management of pT1G3NXM0 transitional cell carcinoma of the bladder. J Urol 2007;178(3 Pt 1):807-13; discussion 13.

[16] Mak KS, Smith A, Eidelmann A, Clayman RH, Heney NM, Sandler HM. Late pelvic toxicity after bladder-sparing therapy in patients with invasive bladder cancer: RTOG 89-03, 95-06, 97-06, 99-06. J Clin Oncol 2004;22(2):356-61.

[17] Gunn MA, Griepp RB, Hirschl RB, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 2002;16(2):137-48.

[18] Hafermann MD, Hawkins IR. Superficial bladder cancer: Is immediate cystectomy always necessary? BJU Int 2003;92(2):79-85.

[19] Saint F, Salomon L, Quintela R, Cicco A, Hoznek A, Birkhauser FD, Rentsch CA, Gsponer JR, Biot C, Renshaw E. Preexisting BCG-specific T cells improve intravesical immunotherapy for bladder cancer. J Immunol 2013;191(2):429-34.

[20] Dunn GP, Bousso P, Albert ML. Cancer immunodominance: From immunosurveillance to tumor escape. Nat Immunol 2002;3(11):991-8.

[21] Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 2004;21(2):137-48.

[22] Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry BM, Royal RE, Topalian SL, Kammula US, Rezolo NP, Zheng Z, Nakato A, de Vries CR, Rosenberg LS. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006;314(5796):126-9.

[23] Bousso P, Demangel C, Peduto L, Thalmann GN, Albert ML. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 2013;369(8):735-43.

[24] Kaijun Zhang, Xing Sha, Fei Wu, Rui Fei, Wei Cao, Guoqiang Hu, Honglong Zhao, et al. Immunotherapy for bladder cancer: Establishment of a predictive profile in a Southern European population. BJU Int 2014 Jun 16 [cited 2015 Feb 15]. doi: 10.1111/bju.12844 [Epub ahead of print].
B. Z. Buchwald and J. A. Efstathiou / Immunotherapy / Radiotherapy

25

[42] Kim YJ, Ha YS, Kim SK, Yoon HY, Lim MS, Kim MI, Moon SK, Choi YH, Kim WJ. Gene signatures for the prediction of outcome of Bacillus Calmette-Guerin immunotherapy in primary T1 bladder cancers. Clin Cancer Res 2010;16(7):2311-7.

[43] Wei H, Kamat A, Chen M, Ke HL, Chung DW, Yin J, Grossman HB, Denney CP, Wu X. Association of polymorphisms in cytokine genes with clinical outcomes for bladder cancer treated with Bacillus Calmette-Guerin. PLOS ONE 2012;7(12):e58533.

[44] van der Meijden AP, Syrbeaten RJ, Oosterlink W, Hoeltl W, Bono AV, Group EGI-UTC. Maintenance Bacillus Calmette-Guerin for T1 bladder tumors is not associated with increased toxicity: Results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III Trial. Eur Urol 2003;44(4):429-34.

[45] Wijes JA. Management of BCG failures in superficial bladder cancer: A review. Eur Urol 2006;49(3):790-7.

[46] Rohle A, Jochum D, Bock PR. Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: A meta-analysis of comparative studies on recurrence and toxicity. J Urol 2003;169(1):98-9.

[47] Syrbeaten RJ, van der Meijden AP, Wijes JA, Korth K. Bacillus calmette-guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: A meta-analysis of the published results of randomized clinical trials. J Urol 2005;174(1):86-91; discussion 91-2.

[48] Herr JW, Dalbgra D. Defining bacillus Calmette-Guerin refractory superficial bladder tumors. J Urol 2003;169(5):1706-8.

[49] Zitola AR, Fliesner NE, Jowett MA. The management of BCG failure in non-muscle-invasive bladder cancer: An update. Can Urol Assoc J 2009;3(6 suppl 4):S199-205.

[50] Zitola AR, Dauwer A, Hergen K, Dr Beyras J, Shakerasra H, Decok M, Peron M, Juton J, Pafflet K, Denis O, Mascart F, Simon C, Schulman CC, Van Vossem JP. Humoral response against heat shock proteins and other mycobacterial antigens after intravesical treatment with bacille Calmette-Guerin in patients with superficial bladder cancer. Clin Exp Immunol 1997;109(1):157-65.

[51] O’Donnell MA, Lili K, Lepold C, National Bacillus Zlotta AR, Drowart A, Huygen K, De Bruyn J, Herr HW, Dalbagni G. Defining bacillus Calmette-Guerin immunotherapy. J Immunol 1999;163(8):4246-52.

[52] Lawrence MS, Sosman JA, Pollock P, Kryvsky CV, Cibulskis K, Sporten A, Carter SL, Stewart C, Mermel CH, Roberts SA, Kicuan A, Hammersman PS, McKenna A, Drier Y, Zou L, Ramos AH, Pugh TJ, Stranay N, Heiman E, Kim J, Sougnez C, Ambrosio L, Nickerson E, Sheller E, Cottis ML, Auclair D, Sakaone G, Yost D, Nofler M, Dacarr D, Lin P, Lichtenson L, Heiman DL, Femtel T, Immelius M, Hernandez B, Hoks E, Baar S, Dukia AH, Lofor J, Landau DA, Wu CI, Melendez-Zaiga L, Hidalgo-Medina A, Koren A, McCarthy SA, Mora J, Lee RS, Crompton B, Oetofrin R, Parkin M, Winkelner W, Auell A, Gabriel SB, Roberts CW, Biegel JA, Stegmaier K, Baus AJ, Garraway LA, Meytsson M, Golub TB, Gordenna DA, Sunyav S, Lundor ES, Cett G. Mutational heterogeneity in bladder cancer and the search for new cancer-associated genes. Nature 2013;499(7475):214-8.

[53] Kandolt B, McMillan MD, Vaidyan F, Ye Y, Niu B, Lu C, Xie M, Zhang Q, McMichael JF, Wyzaykowska MA, Leeson MD, Miller CA, Welch JS, Walter MJ, Wood MC, Ley TJ, Wilson RK, Raphoel B, Ding L. Mutational landscape and significance across 12 major cancer types. Nature 2013;502(7474):333-9.

[54] Choueiri TK, Ross RW, Jacobs M, Vashishpany U, Ye EA, Quinn DH, Hanh NM, Huettel TE, Sonpavde G, Morrissey SC, Buckle GC, Kim WW, Petrylak DP, Ryan CW, Eisenberger MA, Montazzi A, Rubley AG, Taplin ME, Rosenberg JE, Kantoff PW Double-blind, randomized trial of docetaxel plus vincristine versus docetaxel plus placebo in platinum-pre-treated metastatic urothelial cancer. J Clin Oncol 2012;30(34):507-12.

[55] Bellmunt J, Theodorou C, Dimoukos T, Kornasby R, Songerlof L, Daneshmand F, Carlucci D, Miracco C, Voltier L, Biagioli M, Altomonte M, Maio M. Therapeutic efficacy of Ipilimumab (anti-CTLA-4) treatment leads to clinical activity in metastatic urothelial cancer. J Clin Oncol 2010;28:4454-61.

[56] Powles T, Eder JP, Fine GD, Bratianu FS, Lisav Y, Cruz C, Bellmunt J, Burns HA, Petrylak DP, Trong SL, Shen X, Boyd Z, Heiple PR, Christofori G, Vang SG, Vogelzang NJ. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 2014;515(7528):558-62.

[57] Di Giacomo AM, Danielli R, Guidoboni M, Calabro L, Carlucci D, Miracco C, Volterrani L, Orlandi MA, Lohr J, Landau E, Heiman DI, Fennell T, Imielinski M, Hernandez B, Hoks E, Baca S, Dukia AH, Lofor J, Landau DA, Wu CI, Melendez-Zaiga L, Hidalgo-Medina A, Koren A, McCarthy SA, Mora J, Lee RS, Crompton B, Oetofrin R, Parkin M, Winkelner W, Auell A, Gabriel SB, Roberts CW, Biegel JA, Stegmaier K, Baus AJ, Garraway LA, Meytsson M, Golub TB, Gordenna DA, Sunyav S, Lundor ES, Cett G. Mutational heterogeneity in bladder cancer and the search for new cancer-associated genes. Nature 2013;499(7475):214-8.

[58] Reinhold WC, ELLerfeldt R, Li Y, Schuttep C, Coleman SM, Bubley GJ, Taplin ME, Rosenberg JE, Kantoff PW, Double-blind, randomized trial of docetaxel plus vincristine versus docetaxel plus placebo in platinum-pre-treated metastatic urothelial cancer. J Clin Oncol 2009;27(27):4584-61.

[59] Tredwell J, Eder JP, Fine GD, Bratianu FS, Lisav Y, Cruz C, Bellmunt J, Burns HA, Petrylak DP, Trong SL, Shen X, Boyd Z, Heiple PR, Christofori G, Vang SG, Vogelzang NJ. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 2014;515(7528):558-62.

[60] Di Giacomo AM, Danielli R, Guidoboni M, Calabro L, Carlucci D, Miracco C, Volterrani L, Orlandi MA, Lohr J, Landau E, Heiman DI, Fennell T, Imielinski M, Hernandez B, Hoks E, Baca S, Dukia AH, Lofor J, Landau DA, Wu CI, Melendez-Zaiga L, Hidalgo-Medina A, Koren A, McCarthy SA, Mora J, Lee RS, Crompton B, Oetofrin R, Parkin M, Winkelner W, Auell A, Gabriel SB, Roberts CW, Biegel JA, Stegmaier K, Baus AJ, Garraway LA, Meytsson M, Golub TB, Gordenna DA, Sunyav S, Lundor ES, Cett G. Mutational heterogeneity in bladder cancer and the search for new cancer-associated genes. Nature 2013;499(7475):214-8.
Z.S. Buchwald and J.A. Efstathiou / Immunotherapy and Radiation

[75] Powderly JD, Koeppen H, Hodi FS, Sosman JA, Gettinger SN, Desai R, Tabernero J, Soria J-C, Hamid O, Freeman GJ, Signoretti S, Association of PD-L1 expression on tumor infiltrating mononuclear cells and overall survival in patients with urothelial carcinoma. Ann Oncol 2015;26(4):812-7.

[76] Foxman TM, Thompson JA, Porous GI, Gonzalez EJ, Pulini J, Dolled-Filhart M, Emancipator LG, Carthon BC, Wolchok JD, Yuan J, Kamat A, Ng Tang DS, Victor CT, Rech AJ, Maity A, Rengan R, Pauken KE, Desai R, Tabernero J, Soria J-C, Hamid O, Fine GD, Hwu WJ, Kefford R, Saxman SB, Propert KJ, Einhorn LH, Crawford ED, Tan-Knock I, Raghavan D, Loubrier F, Sr., Trump D, Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with melphalan, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: A cooperative group study. J Clin Oncol 1997;15(7):2564-9.

[77] Ramesh N, Ge Y, Emerit DL, Zhu M, Mims M, Gandhi S, Ready PS, Ya DC. CG0070, a conditionally replicating granulocyte macrophage colony-stimulating factor–armed oncolytic adenovirus for the treatment of bladder cancer. Clin Cancer Res 2006;12(1):305-13.

[78] Weintraub MD. Li QQ, Agarwal PK. Advances in immunotherapy for the treatment of non-muscle invasive bladder cancer (Review). Mol Clin Oncol 2014;2(5):656-60.

[79] Burke JM, Lamm DL, Mong-MP, Nomura JA, Stephenson JJ, Arsenault JC, Aimi J, Lerner S, Yang AW, Kazarian T, Maclaren DJ, McKernan JM. A first in human phase 1 study of CG0070, a GM-CSF expressing oncolytic adenovirus, for the treatment of nonmuscle invasive bladder cancer. J Urol 2012;188(6):2391-7.

[80] Vater RE, Cooper BT, Vannoppe-Box C, Demarais G, Formenti SC. Combinations of immunotherapy and radiation in cancer therapy. Front Oncol 2014;4:325.

[81] Golden EB, Formenti SC. Radiation therapy and immunotherapy: Growing pains. Int J Radiat Oncol Biol Phys 2012;188(6):2391-7.

[82] Golden EB, Plickert C, Demarais S, Barcellos-Hoff MH, Formenti SC. The convergence of radiation and immunologic cell death signaling pathways. Front Oncol 2012; 2:38.

[83] Vatner RE, Cooper BT, Vannoppe-Box C, Demarais G, Formenti SC. Combinations of immunotherapy and radiation in cancer therapy. Front Oncol 2014;4:325.

[84] Aretloth L, Ghebremedhin T, Almen M, Orel M, Corti A, Siroli M, Migone T, Sierotp E, Formenti SC. Generation of epitope loss variants. J Immunol 2000;165(10): 6560-7.

[85] Tumor PC, Haris CL, Karihaloo K, Petricca E, Taylor RJ, Robert L, Cleveland JL, Lance EA, Spauke MG, Henry G, Corbinan V, West AN, Caramella M, Kivork C, Seja E, Cherry G, Gutierrez R, Carmona M, Xiao Y, Mokatrin A, Koeppen H, Hegde PS, Patsch D, Amaravadi RK, Schuchter LM, Ishwaran H, Mckay B, Pyrma DA, Xu X, Feldman MD, Glass JM, Zhang S, Pizzolo J, Hwu WJ, Kefford R, Saxman SB, Propert KJ, Einhorn LH, Crawford ED, Tan-Knock I, Raghavan D, Loubrier F, Sr., Trump D, Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with melphalan, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: A cooperative group study. J Clin Oncol 1997;15(7):2564-9.

[86] Golden EB, Plickert C, Demarais S, Barcellos-Hoff MH, Formenti SC. The convergence of radiation and immunologic cell death signaling pathways. Front Oncol 2012; 2:38.

[87] Vatner RE, Cooper BT, Vannoppe-Box C, Demarais G, Formenti SC. Combinations of immunotherapy and radiation in cancer therapy. Front Oncol 2014;4:325.
Kwon ED, Drake CG, Scher HI, Fizazi K, Bossi A, van den Barker CA, Postow MA. Combinations of radiation therapy and immunotherapy in castrate-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): A multicenter, randomised, double-blind, phase 3 trial. Lancet Oncol 2014;15(7):780-92.

Liang H, Deng L, Chmura S, Barretta B, Laidis N, Durgan T, Bioclet MA, Lingen MW, Witt M, Weichselbaum RR, Fu YX. Radiation-induced equilibrium is a balance between tumor cell proliferation and T cell-mediated killing. J Immunol 2013;190(11):5874-81.

Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, Sagal SN, Ayari CE, Gordon RA, Bied K, Burke MM, Caldwell A, Kemeny SA, Ayatswbang BU, Zhang X, Lowy I, Inzenstadt HA, Fechy W, Horak CE, Hong Q, Korman AI, Wagginton JM, Gupta A, Staud M, Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013;369(2):122-33.

Hammers HJ, Plimack ER, Infante JR, Eom M, Rini BI, McDermott DF, Rataf SKA, Pal SK, Yosse WK, Sharma P, Kollmannsberger CK, Hok HVC, Sellar JL, Shen Y, Kurland JF, Gagner P, Amin A. Phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mRCC). ASCO Meeting Abstracts 2014;32(5):4508.

Dovsek SJ, Auland AL, Lipowska-Bihaliga G, McKenna C, Jones S, Cheallie EJ, Stratford IL, Poos E, Morrow M, Stewart R, Jones H, Wilkinson RW, Honeychurch J, Elley TM. Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-1/L1 blockade. Cancer Res 2014;74(19):5458-68.

Dewar MZ, Galloway AE, Kawashima N, Desyngaart JK, Babb JS, Formenti SC, Demaria S. Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin Cancer Res 2009;15(17):5379-88.

Dovsek SJ, Milla MB, Wilkinson RW, Auland AL, Stratford IL, Honeychurch J, Elley TM. Systematic delivery of a TRAIL agonist in combination with radiation primes durable anti-tumor immune responses in murine models of lymphoma. Blood 2013;121(2):251-9.

Goldin EB, Demaria S, Schull PB, Chachoua A, Formenti SC. An abscopal response to radiation and ipilimumab in a patient with metastatic non-small-cell lung cancer. Cancer Immunol Res 2013;1(3):365-72.

Postow MA, Callahan MK, Barker CA, Yamada Y, Yuan J, Koiro S, Ma Z, Rosalian T, Adamson M, Ritter E, Sedrak C, Jungbluth AA, Chau R, Yang AS, Roman RA, Rooser S, Benson B, Allison JP, Lesokhin AM, Orjicza S, Wolchok JD. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med 2012;366(10):925-31.

Schafer D, Raittkan J, Jwonic KS,微丸WH. Maximizing tumor immunity with fractionated radiation. Int J Radiat Oncol Biol Phys 2012;83(4):1386-90.

Lugade AA, Sorensen EW, Gerber SA, Moran JP, Fiebiginger JG, Lord EM. Radiation-induced IFN-gamma production within the tumor microenvironment influences antitumor immunity. J Immunol 2008;180(5):312-9.